Anti-HER2/neu peptide producing vector system for biologic therapy - Is it possible to mass-produce the peptide?

Yonsei Medical Journal

Volumn 44, Issue 1, 2003, Pages 58-64

  Park, Byeong Woo ^a   Kim, Ki Suk ^a   Heo, Min Kyu ^a   Lee, Kyong Sik ^a   Kim, Eun Kyung ^a   Kim, Kyung Sup ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Biologic therapy; HER2 neu; Mimetic peptide

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; TRASTUZUMAB;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; ESCHERICHIA COLI; GENE CONSTRUCT; GENE OVEREXPRESSION; GENE SEQUENCE; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE NEU; PROTEIN PURIFICATION; RECEPTOR BINDING; TUMOR CELL;

EID: 0037296884     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2003.44.1.58     Document Type: Article

References (27)

1. Plowman GD, Whitney GS, Neubauer MG, Green JM, McDonald VL, Todaro GJ, et al. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci USA 1990;87: 4905-9.
2. Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 1993;90:1746-50.
3. Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, et al. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 1997;16:4938-50.
4. Tzahar E, Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1998; 1377:M25-37.
5. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 1994;9:2109-23.
6. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985;41:697-706.
7. Drebin JA, Link VC, Weinberg RA, Greene MI. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 1986;83:9129-33.
8. Disis ML, Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 1997;71:343-71.
9. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA 1991;88:8691-5.
10. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 1997;14: 2099-109.
11. Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 1988;2:387-94.
12. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58: 2825-31.
13. Cho MJ, Juliano R. macromolecular versus small-molecule therapeutics: drug discovery, development and clinical considerations. Trends Biotechnol 1996;14: 153-8.
14. Park BW, Zhang HT, Wu C, Berezov A, Zhang X, Dua R, et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol 2000;18:194-8.
15. Hruby VJ. Conformational and Topographical considerations in the design of biologically active peptides. Biopolymers 1993;33:1073-82.
16. Langston S. Peptidomimetics and small molecule design. Drug Discov Today 1997;2:254-6.
17. Qabar M, Urban J, Sia C, Klein M, Kahn M. Peptide secondary structure mimetics: applications to vaccines and pharmaceuticals. Farmaco 1996;51:87-96.
18. Murali R, Greene MI. Structure-based design of immunologically active therapeutic peptides. Immunol Res 1998;17:163-9.
19. Moore GJ. Designing peptide mimetics. Trends Pharmacol Sci 1994;15:124-9.
20. Kieber-Emmons T, Murali R, Greene MI. Therapeutic peptides and peptidomimetics Curr Opin Biotechnol 1997;8:435-41.
21. Berezov A, Zhang HT, Greene MI, Murali R. Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. J Med Chem 2001;44:2565-74.
22. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989;119:203-10.
23. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant pressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
24. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastaic breast cancer that has progressed after chemotherpy for metastaic disease. J Clin Oncol 1999;27:2639-48.
25. Jain RK. Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies. J Natl Cancer Inst 1989;81:570-6.
26. Vaisman N, Nissim A, Klapper LN, Tirosh B, Yarden Y, Sela M. Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. Immunol Lett 2000;75:61-7.
27. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996;273:458-64.